Table 2.
Clinical trials with mAbs targeting chemokine receptors
| Receptor/mAbs | Epitope | Isotype | Pathological condition(s) | Phase | Trial (PMID) | Status |
|---|---|---|---|---|---|---|
| CCR2 | ||||||
| MLN1202 | N.a. | IgG1 | Metastatic cancer | II | NCT01015560 | S |
| Atherosclerotic cardiovascular disease | II | NCT00715169 | C | |||
| Multiple sclerosis | II | NCT01199640 | C | |||
| CCR4 | ||||||
| KW-0761 | Nt | IgG1 | Adult T-cell leukaemia-lymphoma and peripheral T-cell lymphoma | I + II | NCT00920790 | O |
| NCT00355472 | O | |||||
| NCT00888927 | O | |||||
| KW-0761 + multidrug chemotherapy | Peripheral and cutaneous T-Cell lymphoma | II | NCT01226472 | R | ||
| Peripheral T/NK-cell lymphoma | II | NCT01192984 | R | |||
| Adult T-cell leukaemia-lymphoma | II | NCT01173887 | R | |||
| CCR5 | ||||||
| HGS004/CCR5mAb004 | EL2 | IgG4 | HIV infection | I | NCT00114699 | C |
| PRO140 | Nt & EL2 | IgG1 | HIV infection | I + II | NCT00110591 | C |
| NCT00613379 | C | |||||
| NCT00642707 | C | |||||
| PRO140 + oral antiretroviral therapy | HIV infection | II | NCT01272258 | R | ||
| CXCR4 | ||||||
| MDX-1338 | N.a. | N.a. | Acute myeloid leukaemia | I | NCT01120457 | R |
Info obtained in January 2011 on http://www.clinicaltrials.gov. Epitope indicates the receptor region involved in mAb recognition: Nt, N-terminus; N.a., information not available. Status of clinical trials: C, completed; O, ongoing; R, recruiting; S, suspended.